for Oxylanthanum Carbonate (OLC). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025. If approved, OLC has the potential to meaningfully improve the ...

Title: Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary ... The study demonstrated potent effects of the novel lanthanum-based phosphate binder OLC and found that OLC plus tenapanor ...

OLC is being developed as a more patient-friendly alternative to Takeda's phosphate binder Fosrenol (lanthanum carbonate), which is sold in a large chewable tablet formulation, while other drugs ...

A 57-year-old dialysis-dependent man listed for transplantation presented for diagnostic endoscopy; he had no abdominal symptoms. The examination revealed a clearly coarsened gastric mucosa with ...